12 results about "Procalcitonin" patented technology

The invention relates to a sepsis detection system which evaluates the sepsis risk of a patient in real time by integrating clinical signs, various physiological parameters, laboratory detection data and biomarkers and utilizing an intelligent algorithm. The system comprises a data acquisition module, a data transmission module, a data processing module, a user display module and an alarm module. The data acquisition module monitors physiological parameters such as consciousness, body temperature, heart rate, respiratory rate, finger pulse oxygen saturation, invasive blood pressure, urine volume and skin piebald in real time, and biomarker data such as leukocyte count, neutrophile granulocyte, neutrophile granulocyte number, C-reactive protein, procalcitonin and interleukin-6 are obtained through blood detection. And the data processing module performs sepsis risk assessment by integrating the biomarkers and the physiological parameters in combination with a machine learning model, and outputs a risk level. The user display module displays the evaluation result in real time and provides treatment suggestions, and the alarm module triggers an alarm under the high-risk condition to ensure timely intervention.

This application discloses a chemiluminescence detection kit for acrylonitrile magnetic microparticles and its detection method. The kit includes a magnetic bead working solution and a luminescent label. The magnetic bead working solution includes acrylonitrile monoclonal antibody A and streptavidin. The luminescent label includes acrylonitrile monoclonal antibody B, modified nano-silica, anhydrous toluene, methoxy polyethylene glycol-succinimide ester, N,N-dimethylformamide, acrylonitrile succinimide ester, glutaraldehyde, and ethanolamine. This application uses modified nano-silica as a carrier and grafts a polyethylene glycol hydrophilic layer onto its surface, which amplifies the acrylonitrile ester molecule signal, reduces non-specific adsorption, and improves the sensitivity, specificity, and reliability of the detection.

According to this invention, there is provided an automated sample preparation system implemented within a disposable cartridge. The system utilizes finger prick blood or venous blood as an input sample and performs various sample processing steps, including fluidic metering, fluidic routing, and reagent storage with an integrated biosensor. The architecture, of this system, enables efficient and accurate testing of blood parameters, hematology parameters such as CBC, CD4-T cells count, but not limited to, Complete Blood Cell Count (CBC) and measurement of biomarkers such as Troponin, IL-6, Procalcitonin, but not limited to, CRP, Procalcitonin, and IL-6 through ELISA and is flexible to implement other electrochemistry techniques.

Disclosed herein are methods for subtyping patients with a respiratory infection (e.g., community acquired pneuomonia or severe acute respiratory infection) to identify likely responders to corticosteroid therapy. The methods involve analyzing values of a plurality of biomarkers, examples of which include a first biomarker selected from procalcitonin, IL-6, and TREM-1, and a second biomarker selected from Pentraxin-3, MIP-3α, IL-1ra, IL-8, and NGAL. The methods enable personalized treatment decisions for patients with respiratory infections, potentially improving patient outcomes by targeting corticosteroid therapy to those most likely to benefit while avoiding harm to non-responders.

This application belongs to the field of diagnostic reagent technology, and particularly relates to a calibrator buffer solution, calibrator, and reagent kit for procalcitonin detection kit. The calibrator buffer solution for procalcitonin detection kit provided by this application has good stability for preserving procalcitonin antigen stock solution, while avoiding the lyophilization process, reducing the manufacturer's process flow and costs, and improving the user experience by eliminating the need for reconstitution. As a buffer solution specifically for procalcitonin calibrators, it can solve the technical problem in the prior art where the need for reconstitution of lyophilized powder calibrators leads to excessive detection errors.

Disclosed is a composition for the treatment of hypercalcitonemia, the composition comprising a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and comprising or without one or more electrolytes wherein the amphiphilic emulsifier forms: a micelle in a polar liquid carrier, the micelle is provided with a lipophilic or hydrophobic core containing a lipophilic or hydrophobic component; and / or self-assembling to form lipidosome with a lipid bilayer structure; and / or other particle configurations.

A diagnostic reagent for quantitatively determining procalcitonin in a sample, suitable for simple photometric turbidimetric analysis and with high sensitivity for quantitatively determining procalcitonin in a sample, comprising an aqueous suspension of polymer particles to which an antibody against procalcitonin is covalently bound, wherein the tendency for aggregation / sedimentation is not detectable or is negligible even after prolonged standing, and the specific reactivity of the particles remains substantially unchanged. To provide such a diagnostic reagent, it is proposed according to the present invention that the suspended polymer particles have an average particle size in the range of 150-450 nm, the suspension comprises a proportion of dissolved sugar or sugar alcohol in the range of 25-250 g / l, and the suspension has a pH in the range of 8-10.

The invention relates to the field of hepatobiliary postoperative infection risk grading early warning, in particular to a hepatobiliary postoperative infection risk grading early warning method based on clinical parameters. The method comprises the steps that original clinical parameters are collected and preprocessed, and preprocessed standardized clinical parameters are obtained; a clinical basic weight is introduced, and based on the preprocessed standardized clinical parameters, an infection risk score is obtained through calculation by applying a multi-dimensional distribution mapping algorithm; and risk grades are divided based on infection risk scores, a dynamic weighting mechanism emphasizing effective updating is introduced, and clinical basic weights are dynamically updated. The problems that a traditional hepatobiliary postoperative infection risk assessment method neglects complex high-order interaction and non-linear correlation among indexes such as body temperature, leukocyte count, procalcitonin and C-reactive protein, cannot adjust parameter weights in real time according to dynamic changes of postoperative illness states of patients, lacks a clear risk grading rule and is poor in risk assessment accuracy are solved. And the engineering application value is limited.

This application belongs to the field of microbial technology, specifically disclosing the application of *Lactobacillus fermentum* BLF03 in anti-Candida activity. *Lactobacillus fermentum* BLF03 was deposited on November 6, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 36521. This application proposes a *Lactobacillus fermentum* BLF03 strain resistant to *Candida albicans* and *Candida krusei*, which can significantly inhibit the growth, reproduction, and hyphal transformation of *Candida albicans* and *Candida krusei* at the in vivo level, alleviate Candida-induced infection symptoms, reduce the expression level of the inflammatory marker procalcitonin (PCT) after Candida infection, improve the inflammatory stress response induced by infection, and has a significant protective effect against tissue damage caused by Candida invasion. It also has targeted preventive and adjunctive therapeutic effects on Candida infections in the urogenital tract and other sites, providing a new, safe, and highly effective strain for anti-Candida products.

The present application relates to the field of postoperative infection risk grading and early warning of hepatobiliary surgery, and in particular to a postoperative infection risk grading and early warning method based on clinical parameters. The content includes: collecting original clinical parameters and preprocessing to obtain preprocessed standardized clinical parameters; introducing a clinical basic weight, based on the preprocessed standardized clinical parameters, applying a multidimensional distribution mapping algorithm to calculate an infection risk score; dividing the risk level based on the infection risk score, and introducing a dynamic weighting mechanism with emphasis on effective updating to dynamically update the clinical basic weight. The method solves the problems of traditional postoperative infection risk assessment methods for hepatobiliary surgery, such as ignoring the complex high-order interaction and nonlinear correlation between body temperature, white blood cell count, procalcitonin, C-reactive protein and other indicators, being unable to adjust the parameter weight in real time according to the dynamic changes of the patient's postoperative condition, and lacking clear risk grading rules and limited engineering application value.

The invention discloses a model for early prediction of acute kidney injury risk after a sepsis patient is transferred into ICU based on clinical variables and immune inflammation indicators, and an immune-clinical model is established by adopting an XGBoost algorithm based on data of 1551 domestic sepsis patients in 24 hours after the sepsis patient is transferred into the ICU so as to predict the risk of SA-AKI of the patient. The model integrates five clinical variables including procalcitonin, APACHE II, SOFA score, gender and prothrombin time and four immune inflammation indexes including IgA, complement C3, Nave CD4 + T% and CD28 + CD4 + T%, the average ROC-AUC value is 0.914, an SHAP method is introduced to generate a feature importance map and an individual prediction interpretation map, the contribution degree of each index to risk prediction of a specific patient can be visually displayed, the cause of SA-AKI of the patient can be explained, and the risk of the specific patient can be predicted. Therefore, doctors can take targeted measures preventively.

The invention relates to the technical field of molecular biology, in particular to application of a detection reagent of SatIII RNA and a septicopyemia detection product comprising the detection reagent. The invention particularly relates to application of a detection reagent of SatIII RNA in preparation of a septicopyemia detection product. The invention discloses a brand new biomarker, namely SatIII RNA, which is different from traditional protein markers such as procalcitonin and C-reactive protein. The RNA marker is stable, detection belongs to minimally invasive detection, detection is easy, quantification is accurate, and due to the advantages, the sensitivity and specificity of septicopyemia detection can be improved. The successful development of the RNA marker contributes to the diagnosis, grouping, precise treatment and prognosis of septicopyemia, and also provides reference significance for the research and development of biomarkers of other diseases.